Compare KEY & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEY | ILMN |
|---|---|---|
| Founded | 1825 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.6B | 18.9B |
| IPO Year | N/A | 2000 |
| Metric | KEY | ILMN |
|---|---|---|
| Price | $20.49 | $134.65 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 15 |
| Target Price | $20.25 | ★ $114.93 |
| AVG Volume (30 Days) | ★ 17.9M | 1.6M |
| Earning Date | 01-20-2026 | 10-30-2025 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | ★ 34785.88 | N/A |
| EPS | 0.86 | ★ 4.46 |
| Revenue | ★ $5,934,000,000.00 | $4,288,000,000.00 |
| Revenue This Year | $77.19 | N/A |
| Revenue Next Year | $6.55 | $2.08 |
| P/E Ratio | ★ $23.89 | $30.24 |
| Revenue Growth | ★ 22.30 | N/A |
| 52 Week Low | $12.73 | $68.70 |
| 52 Week High | $20.84 | $153.06 |
| Indicator | KEY | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 75.76 | 68.81 |
| Support Level | $18.26 | $126.44 |
| Resistance Level | $19.73 | $137.09 |
| Average True Range (ATR) | 0.43 | 3.52 |
| MACD | 0.23 | 0.01 |
| Stochastic Oscillator | 87.37 | 81.58 |
With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.